Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of February 2022, with a specific transaction date of February 10, 2022. The report serves as a transaction notification regarding a sale of securities by a Person Discharging Managerial Responsibilities (PDMR).
Key Financial Metrics
The filing does not provide consolidated revenue, profit, cash flow, margins, debt, or liquidity metrics for the company. It reports a single transaction event:
- Instrument: American Depositary Shares (ADSs), ISIN: US37733W1053.
- Transaction Type: Sale.
- Volume: 55,000 ADSs.
- Price: $44.9937 per ADS.
- Exchange: New York Stock Exchange (XNYS).
Material Changes
The filing does not disclose material changes to the company's financial position or operations compared to prior periods. It solely documents a change in beneficial ownership by an executive.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a regulatory disclosure of an insider transaction.
Investor Verification Points
- Verify the identity of the seller: Mr. B McNamara, CEO of GSK Consumer Healthcare.
- Confirm the transaction date of February 10, 2022, and the execution price of $44.9937.
- Note that this filing does not reflect the company's overall financial performance for the period.